Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
HELP
Cybin D/B/A Helus Pharma
Cybin D/B/A Helus Pharma (HELP) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (C).
Quantitative Factor Evaluation • Updated
Overall Rating
2.7
/ 5.0
C+
Value
C+
Factor Score
2.5
/ 5.0
Growth
C+
Factor Score
2.6
/ 5.0
Profitability
C
Factor Score
2.4
/ 5.0
Momentum
B+
Factor Score
3.6
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-5.3
EV / EBITDA
-3.1
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-18.0%
Price Return 12M
47.6%
Catalyst Signal
0.00
Market Cap
$686.1M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-86.9%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C+ (2.6) | C (2.4) | B+ (3.6) | C+ (2.6) | C+ (2.7) |
| 2026-11-05 | C+ (2.5) | C+ (2.5) | C (2.4) | B+ (3.5) | C+ (2.7) | C+ (2.7) |
| 2026-10-29 | C+ (2.5) | C (2.5) | C (2.4) | A+ (4.5) | C+ (2.7) | B- (2.9) |
| 2026-10-22 | C+ (2.5) | C (2.4) | C (2.4) | A+ (4.7) | C+ (2.6) | B- (2.9) |
| 2026-10-15 | C+ (2.5) | C (2.3) | C (2.4) | A+ (4.8) | C+ (2.6) | B- (2.9) |
Page
1
of
4